TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10404912

Group type: COMPARATOR
Intervention: Control group (n = 19): tidal volume to obtain normal values of arterial carbon dioxide tension (35-40 mm Hg) and PEEP producing the greatest improvement in arterial oxygen saturation without worsening hemodynamics.
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Lung-protective strategy group (n = 18): tidal volume and PEEP based on the volume-pressure curve.
Number of subjects: 44
Study: 8624227

Group type: EXPERIMENTAL
Intervention: MFP/DCPD dentifrice (1000 ppm fluoride)
Number of subjects: 12

Group type: COMPARATOR
Intervention: MFP/silica dentifrice (1000 ppm fluoride)
Number of subjects: 12

Group type: COMPARATOR
Intervention: DCPD placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Silica placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: MFP/DCPD dentifrice (250 ppm fluoride)
Number of subjects: 12

Group type: COMPARATOR
Intervention: MFP/DCPD dentifrice (0 ppm fluoride)
Number of subjects: 12
Study: 1963274

Group type: EXPERIMENTAL
Intervention: Pirarubicin 20 mg/m2
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Pirarubicin 24 mg/m2
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Pirarubicin 25 mg/m2
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Pirarubicin 27 mg/m2
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Pirarubicin (all doses)
Number of subjects: 19
Study: 31280990

Group type: EXPERIMENTAL
Intervention: Hydromorphone
Number of subjects: 135

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 135
Study: 29684926

Group type: EXPERIMENTAL
Intervention: Training Group (TG, n=15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control Group (CG, n=15)
Number of subjects: 30
Study: 26194935

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg daily for 28 days
Number of subjects: 403

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Tamsulosin (subgroup analysis for large stones 5 to 10 mm)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Placebo (subgroup analysis for large stones 5 to 10 mm)
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 403
Study: 24495883

Group type: EXPERIMENTAL
Intervention: Intracoronary melatonin administration
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40
Study: 23277643

Group type: EXPERIMENTAL
Intervention: Oridermyl (acaricidal/antibiotic/ antifungal/anti‐inflammatory ointment), treated once daily for 10 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Revolution (selamectin spot‐on), treated on Day 0
Number of subjects: 24
Study: 21049628

Group type: EXPERIMENTAL
Intervention: Group II: Tpanax Notoginseng Pills PO, Lornoxicam For Injection, 8 mg IM
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group III: Tpanax Notoginseng Pills PO, Tong Mai Decoctions 200 mL PO
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group IV: Tpanax Notoginseng Pills PO, Lornoxicam For Injection 8 mg IM, Tong Mai Decoctions 200 mL PO
Number of subjects: 120

Group type: COMPARATOR
Intervention: Group I: Tpanax Notoginseng Pills PO
Number of subjects: 120
Study: 16945983

Group type: EXPERIMENTAL
Intervention: Multi-component educational intervention delivered by health personnel as part of usual care; details on dosage and duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing nutrition education (control group); details on dosage and duration not specified.
Number of subjects: 0
Study: 17877120

Group type: EXPERIMENTAL
Intervention: Carvedilol (12.5 mg/day, 25 mg/day, 50 mg/day) administered in increasing doses every four weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (12 healthy subjects aged 39‐49 years, mean 45.7 years)
Number of subjects: 30
Study: 12121506

Group type: EXPERIMENTAL
Intervention: IFN and GMCSF (group A, n = 10)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: IFN and lamivudine (group B, n = 14)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Overall sustained response
Number of subjects: 24
Study: 10522506

Group type: EXPERIMENTAL
Intervention: Oxymetazoline hydrochloride (0.5 mg/mL) nasal spray containing benzalkonium chloride (0.1 mg/mL)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Oxymetazoline nasal spray without benzalkonium chloride
Number of subjects: 35
Study: 7539822

Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Invasive intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Automatic implantable cardioverter-defibrillator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Class I antiarrhythmic drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antiarrhythmic drugs
Number of subjects: 0
Study: 1971461

Group type: EXPERIMENTAL
Intervention: Benzyl-1 isoquinoline derivative (458 L)
Number of subjects: 12
Study: 7027062

Group type: EXPERIMENTAL
Intervention: 1 alpha-hydroxycholecalciferol (2 micrograms daily for 3 months, then 1 microgram daily for 9 months)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 1 alpha-hydroxycholecalciferol
Number of subjects: 48
Study: 31419239

Group type: EXPERIMENTAL
Intervention: EGFR(+) patients
Number of subjects: 13043

Group type: EXPERIMENTAL
Intervention: EGFR(-) patients
Number of subjects: 13043

Group type: EXPERIMENTAL
Intervention: Nomogram for EGFR(+) patients
Number of subjects: 13043

Group type: EXPERIMENTAL
Intervention: Nomogram for EGFR(-) patients
Number of subjects: 13043
Study: 25467077

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 195
Study: 22677612

Group type: EXPERIMENTAL
Intervention: Prophylactic retention sutures
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (running looped #1 nylon suture)
Number of subjects: 300
Study: 21270743

Group type: EXPERIMENTAL
Intervention: Daily oral antiretrovirals (tenofovir disoproxil fumarate [TDF] and emtricitabine [FTC]) as preexposure prophylaxis (PrEP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19246334

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg/d (RSV10 group)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg/d (RSV20 group)
Number of subjects: 150

Group type: COMPARATOR
Intervention: therapeutic lifestyle modification (nonstatin-treated group)
Number of subjects: 150
Study: 17454156

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg daily from cycle day 3 to day 7
Number of subjects: 33

Group type: COMPARATOR
Intervention: Clomiphene citrate 100 mg daily from cycle day 3 to day 7
Number of subjects: 33
Study: 15114429

Group type: EXPERIMENTAL
Intervention: 75 micro g midazolam
Number of subjects: 21

Group type: COMPARATOR
Intervention: ketoconazole (200 mg b.i.d.)
Number of subjects: 21

Group type: COMPARATOR
Intervention: rifampicin (450 mg q.d.)
Number of subjects: 21
Study: 11826546

Group type: EXPERIMENTAL
Intervention: Fosinopril 10, 20, and 40 mg as monotherapy
Number of subjects: 203
Study: 9558043

Group type: EXPERIMENTAL
Intervention: Nissen fundoplication
Number of subjects: 32
Study: 8034781

Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gel + SCRP
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 40% tetracycline paste + SCRP
Number of subjects: 22

Group type: COMPARATOR
Intervention: SCRP only
Number of subjects: 22
Study: 2539025

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin plus dihydroergotamine mesylate (5,000 IU unfractionated heparin plus 0.5 mg dihydroergotamine mesylate twice daily)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Low-molecular weight heparin plus dihydroergotamine mesylate (1,500 IU low-molecular weight heparin plus 0.5 mg dihydroergotamine mesylate once daily)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Low-molecular weight heparin plus dihydroergotamine mesylate
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin plus dihydroergotamine mesylate
Number of subjects: 200
Study: 31990684

Group type: EXPERIMENTAL
Intervention: Cytotoxic CD4+ T cells
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: CD8+ T cells
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: HLA‐DR‐expressing endothelial cells
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Apoptotic cells
Number of subjects: 35
Study: 30653123

Group type: EXPERIMENTAL
Intervention: Elective nodal irradiation (ENI)
Number of subjects: 644

Group type: COMPARATOR
Intervention: Involved-field irradiation (IFI)
Number of subjects: 644
Study: 29330978

Group type: EXPERIMENTAL
Intervention: Intramuscular diclofenac
Number of subjects: 200

Group type: COMPARATOR
Intervention: Lidocaine injection for sensory blockade
Number of subjects: 200
Study: 25490907

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Cyclophosphamide (CTX)
Number of subjects: 84
Study: 23735819

Group type: EXPERIMENTAL
Intervention: Epoetin-alfa (average weekly doses ranging from 133 to 19,106 units/week)
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Epoetin-alfa (middle tertile of Hb achieved >11.5 to <12.7 g/dl and lowest tertile of epoetin-alfa dose exposure level <5,164 units/week)
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Epoetin-alfa (average weekly dose)
Number of subjects: 1244
Study: 22189410

Group type: EXPERIMENTAL
Intervention: Web-based education over a 4-week period with remote tutor facilitation
Number of subjects: 166

Group type: COMPARATOR
Intervention: Face-to-face traditional education using a 1-day seminar format with additional video and written support material
Number of subjects: 166
Study: 19929119

Group type: EXPERIMENTAL
Intervention: Control of sounds
Number of subjects: 35

Group type: COMPARATOR
Intervention: No control of sounds
Number of subjects: 35
Study: 16825039

Group type: EXPERIMENTAL
Intervention: 6-month supervised nonaggravating exercise program
Number of subjects: 93

Group type: COMPARATOR
Intervention: Usual surgical advice
Number of subjects: 93
Study: 16422971

Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Vardenafil 20 mg
Number of subjects: 732

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Vardenafil 10/20 mg
Number of subjects: 732
Study: 11159876

Group type: EXPERIMENTAL
Intervention: BIM26226 (5-500 microg. kg(‐1). h(‐1))
Number of subjects: 0
Study: 9458563

Group type: EXPERIMENTAL
Intervention: Sterile water
Number of subjects: 148

Group type: COMPARATOR
Intervention: Alcohol
Number of subjects: 148
Study: 8166066

Group type: EXPERIMENTAL
Intervention: Transvenous-SQ pathways (right ventricular cathode to SQ anode and coronary sinus cathode to SQ anode)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Transvenous-transvenous pathways (right ventricle to coronary sinus and right ventricle to superior vena cava)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Epicardial pathways
Number of subjects: 42
Study: 3212422

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 29864043

Group type: EXPERIMENTAL
Intervention: Electrical dry needling, manual therapy (MT), and exercise
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Electrical dry needling
Number of subjects: 242

Group type: COMPARATOR
Intervention: Manual therapy (MT) and exercise
Number of subjects: 242
Study: 26186644

Group type: EXPERIMENTAL
Intervention: Generic formulation of pitavastatin calcium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Branded formulation of pitavastatin calcium
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-fat breakfast
Number of subjects: 0
Study: 25559146

Group type: EXPERIMENTAL
Intervention: Preoperative exercise
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (routine surgical care)
Number of subjects: 60
Study: 23878024

Group type: EXPERIMENTAL
Intervention: Modified grapefruit juice (GFJ) (240 mL)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Original grapefruit juice (GFJ) (240 mL)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Water
Number of subjects: 18
Study: 20185386

Group type: EXPERIMENTAL
Intervention: Etanercept 0.8 mg/kg (<= 50 mg) once weekly for 12 weeks
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 211
Study: 18185506

Group type: EXPERIMENTAL
Intervention: Intact parathyroid hormone (iPTH) levels maintained in the target range of 150-300 pg ml(‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intact parathyroid hormone (iPTH) levels less than 150 pg ml(‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intact parathyroid hormone (iPTH) levels greater than 300 pg ml(‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bone biopsies performed at baseline and after 1 year follow-up
Number of subjects: 0
Study: 17006065

Group type: EXPERIMENTAL
Intervention: Alfentanil 5 microg/kg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Alfentanil 10 microg/kg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Alfentanil 15 microg/kg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Alfentanil 20 microg/kg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 12714797

Group type: EXPERIMENTAL
Intervention: Selegiline treatment
Number of subjects: 43
Study: 10514345

Group type: EXPERIMENTAL
Intervention: Recombinant glucagon (rG) pH 2.0 administered intramuscularly (im)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Recombinant glucagon (rG) pH 2.0 administered subcutaneously (sc)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Recombinant glucagon (rG) pH 2.0
Number of subjects: 41

Group type: COMPARATOR
Intervention: Animal-source glucagon (aG)
Number of subjects: 41
Study: 8949429

Group type: EXPERIMENTAL
Intervention: Calcipotriol cream (50 micrograms/g once daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Calcipotriol cream twice daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Calcipotriol and clobetasone 17-butyrate (0.5 mg/g) creams
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Calcipotriol and betamethasone 17-valerate (1 mg/g) creams
Number of subjects: 40

Group type: COMPARATOR
Intervention: Calcipotriol monotherapy (once daily)
Number of subjects: 40
Study: 2294687

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (walking and jogging at >= 70% maximal heart rate reserve for 1 hour 3 times/week for 12 weeks)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Strength and flexibility training (1 hour of circuit Nautilus training 2 times/week for 12 weeks)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 37
Study: 709569

Group type: EXPERIMENTAL
Intervention: Exercise group (ETG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nontreatment group (NTG)
Number of subjects: 0
Study: 31401654

Group type: EXPERIMENTAL
Intervention: FTO SNP rs9939609 as an instrumental variable in MR models
Number of subjects: 3654

Group type: EXPERIMENTAL
Intervention: Lowest quintile of protein intake
Number of subjects: 3654
Study: 28702809

Group type: EXPERIMENTAL
Intervention: Racemic formoterol (2 × 27 µg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 25282578

Group type: EXPERIMENTAL
Intervention: Computerized brief intervention (CBI)
Number of subjects: 360

Group type: COMPARATOR
Intervention: In-person brief intervention (IBI)
Number of subjects: 360
Study: 24963111

Group type: EXPERIMENTAL
Intervention: Salsalate (3.5 g daily for 4 weeks)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 22704274

Group type: EXPERIMENTAL
Intervention: HbA1c measurement
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure measurement
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure measurement
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Low density lipoprotein measurement
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Comorbidities
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Treatment factors
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: GPs' treatment effect
Number of subjects: 326
Study: 19089782

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 100 mg daily for 5 days
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: Letrozole 5 mg daily for 5 days
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg daily for 5 days
Number of subjects: 796

Group type: COMPARATOR
Intervention: Spontaneous pregnancies (control group)
Number of subjects: 796
Study: 17879495

Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs with oral prednisolone (1 mg/kg body weight for 7 days, tapering off over 3 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Antiepileptic monotherapy
Number of subjects: 100
Study: 15080019

Group type: EXPERIMENTAL
Intervention: ondansetron (4 mg IV and 16 mg in PCA pump)
Number of subjects: 374

Group type: COMPARATOR
Intervention: saline (control group)
Number of subjects: 374
Study: 12479110

Group type: EXPERIMENTAL
Intervention: Tramadol (12 mg/kg) and 0.125% bupivacaine (100 ml) for 48 hours
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Morphine (0.12 mg/kg) and 0.125% bupivacaine (100 ml) for 48 hours
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of tramadol (6 mg/kg), morphine (0.12 mg/kg), and 0.125% bupivacaine (100 ml) for 48 hours
Number of subjects: 120
Study: 9667255

Group type: EXPERIMENTAL
Intervention: 16-week regimen
Number of subjects: 646

Group type: COMPARATOR
Intervention: CAF (cyclophosphamide, doxorubicin, and fluorouracil)
Number of subjects: 646
Study: 8120960

Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study: 3674580

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) 800 micrograms per day
Number of subjects: 26

Group type: COMPARATOR
Intervention: Oral theophylline
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) changed to oral theophylline
Number of subjects: 26
Study: 31844906

Group type: EXPERIMENTAL
Intervention: Multimedia tool in addition to the booklet
Number of subjects: 225

Group type: COMPARATOR
Intervention: Printed booklet alone
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Multimedia tool
Number of subjects: 225
Study: 29247273

Group type: EXPERIMENTAL
Intervention: HRV-guided training hypoxic group (H-HRV)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hypoxia group (H)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normoxia group (N)
Number of subjects: 24
Study: 26639857

Group type: EXPERIMENTAL
Intervention: Newhints intervention (home visits by community-based surveillance volunteers)
Number of subjects: 7848

Group type: EXPERIMENTAL
Intervention: Newhints intervention
Number of subjects: 7848
Study: 24955452

Group type: EXPERIMENTAL
Intervention: Monthly endoscopic variceal ligation (EVL)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Biweekly endoscopic variceal ligation (EVL)
Number of subjects: 70
Study: 23341517

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CRT) with concurrent cisplatin 100 mg/m(2) on days 1, 22, and 43 of RT (arm A)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Bioradiotherapy (BRT) with concurrent cetuximab 400 mg/m(2) loading dose and 250 mg/m(2) per week during RT (arm B)
Number of subjects: 153
Study: 20626512

Group type: EXPERIMENTAL
Intervention: Tunneling excision technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional open method
Number of subjects: 40
Study: 19020701

Group type: EXPERIMENTAL
Intervention: Medical Research Council scale
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Modified Medical Research Council scale
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Maximal relative force measurements
Number of subjects: 31
Study: 18822428

Group type: EXPERIMENTAL
Intervention: Milrinone (loading dose 0.75 microg/kg/min for 3 hours then maintenance 0.2 microg/kg/min until 18 hours after birth)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 90
Study: 15888053

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 23

Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 23
Study: 11893047

Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond 2V (LB)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Prime & Bond 2.1 (PB)
Number of subjects: 3
Study: 8995087

Group type: EXPERIMENTAL
Intervention: Left ventricular dysfunction (ejection fraction < or = 28 percent)
Number of subjects: 2231

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 2231

Group type: EXPERIMENTAL
Intervention: Lower ejection fraction
Number of subjects: 2231

Group type: EXPERIMENTAL
Intervention: Absence of aspirin or anticoagulant therapy
Number of subjects: 2231

Group type: COMPARATOR
Intervention: Thrombolytic agents and captopril
Number of subjects: 2231

Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy
Number of subjects: 2231
Study: 9371324

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Myeloid growth factors
Number of subjects: 2
Study: 2959716

Group type: EXPERIMENTAL
Intervention: Immediate coronary angioplasty
Number of subjects: 386

Group type: COMPARATOR
Intervention: Elective coronary angioplasty (7 day)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator (rt-PA)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Emergency coronary bypass surgery
Number of subjects: 386
Study: 30763405

Group type: EXPERIMENTAL
Intervention: Praziquantel treatment before immunisation
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Praziquantel treatment at immunisation
Number of subjects: 254

Group type: COMPARATOR
Intervention: S. mansoni-infected children
Number of subjects: 254